Oncology ESMO 2024 - Sven Schaffer The European Society for Medical Oncology (ESMO) 2024 meeting was a well-attended affair at the sprawling Fira Gran Via centre in Barcelona.
Oncology ESMO 2024 – Today’s oncological roots are branching What could a tree possibly reveal about the European Society for Medical Oncology (ESMO)?
Oncology CDK9 inhibitors: Disrupting cancer cell growth and the treat... We have made significant strides in cancer treatment in the last decade and a half.
Oncology ASCO 2024 - Matteo Levisetti ASCO 2024 marked the 10th anniversary of checkpoint inhibitors, which powerfully changed the nature of cancer immunotherapy.
Oncology Chimeric antigen receptor T-cells: Emerging uses and future ... Genetic engineering technologies allow for the creation of custom-made cells that can have transformative effects on human health.
Oncology ASCO 2024 - Chris Haqq ASCO isn’t just a show for top 10 pharmas and Phase 3 readouts; it’s also a conference where smaller biopharmas share encouraging early-stage results, especially those that point to a new p
News Eisai debuts biliary tract cancer drug in Japan Eisai has launched its new therapy for biliary tract cancer (BTC) Tasfygo in Japan, the first world market for the FGFR-targeting drug
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
